Status:
COMPLETED
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Lead Sponsor:
Pfizer
Conditions:
Overactive Bladder Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial will provide long-term data on safety, satisfaction and maintenance on therapy of fesoterodine (SPM 907) in subjects with overactive bladder syndrome. Subjects completing the 12 week treat...
Eligibility Criteria
Inclusion
- Participated in SP583
Exclusion
- Failure to complete 12 week treatment with SPM 907
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00220402
Start Date
July 1 2004
End Date
July 1 2007
Last Update
November 24 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
Monheim, Germany